Valsts: Amerikas Savienotās Valstis
Valoda: angļu
Klimata pārmaiņas: NLM (National Library of Medicine)
RABEPRAZOLE SODIUM (UNII: 3L36P16U4R) (RABEPRAZOLE - UNII:32828355LL)
Mylan Pharmaceuticals Inc.
RABEPRAZOLE SODIUM
RABEPRAZOLE SODIUM 20 mg
ORAL
PRESCRIPTION DRUG
Rabeprazole sodium delayed-release tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of rabeprazole sodium delayed-release tablets may be considered. Rabeprazole sodium delayed-release tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD Maintenance). Controlled studies do not extend beyond 12 months. Rabeprazole sodium delayed-release tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with GERD in adults for up to 4 weeks. Rabeprazole sodium delayed-release tablets are indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks. Rabeprazole
Rabeprazole Sodium Delayed-Release Tablets are available containing 20 mg of rabeprazole sodium, USP. The 20 mg tablets are beige, film-coated, round, unscored tablets with M over R7 imprinted in black ink on one side of the tablet and blank on the other side. They are available as follows: NDC 0378-6709-93 bottles of 30 tablets NDC 0378-6709-77 bottles of 90 tablets NDC 0378-6709-05 bottles of 500 tablets Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. PHARMACIST: Dispense a Medication Guide with each prescription.
Abbreviated New Drug Application
Mylan Pharmaceuticals Inc. ---------- MEDICATION GUIDE Rabeprazole Sodium Delayed-Release Tablets (ra bep′ ra zole soe′ dee um) What is the most important information I should know about rabeprazole sodium delayed-release tablets? You should take rabeprazole sodium delayed-release tablets exactly as prescribed, at the lowest dose possible and for the shortest time needed. Rabeprazole sodium delayed-release tablets may help your acid-related symptoms, but you could still have serious stomach problems. Talk with your doctor. Rabeprazole sodium delayed-release tablets can cause serious side effects, including: • A type of kidney problem (acute interstitial nephritis). Some people who take proton pump inhibitor (PPI) medicines, including rabeprazole sodium delayed-release tablets, may develop a kidney problem called acute interstitial nephritis that can happen at any time during treatment with rabeprazole sodium delayed-release tablets. Call your doctor right away if you have a decrease in the amount that you urinate or if you have blood in your urine. • Diarrhea caused by an infection (Clostridium difficile) in your intestines. • Call your doctor right away if you have watery stools or stomach pain that does not go away. You may or may not have a fever. • Bone fractures (hip, wrist, or spine). Bone fractures in the hip, wrist, or spine may happen in people who take multiple daily doses of PPI medicines and for a long period of time (a year or longer). Tell your doctor if you have a bone fracture, especially in the hip, wrist, or spine. • Certain types of lupus erythematosus. Lupus erythematosus is an autoimmune disorder (the body’s immune cells attack other cells or organs in the body). Some people who take PPI medicines, including rabeprazole sodium delayed-release tablets, may develop certain types of lupus erythematosus or have worsening of the lupus they already have. Call your doctor right away if you have new or worsening joint pain or a rash on your cheeks or arms that gets worse in the sun. T Izlasiet visu dokumentu
RABEPRAZOLE SODIUM- RABEPRAZOLE TABLET, DELAYED RELEASE MYLAN PHARMACEUTICALS INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE RABEPRAZOLE SODIUM DELAYED- RELEASE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR RABEPRAZOLE SODIUM DELAYED-RELEASE TABLETS. RABEPRAZOLE SODIUM DELAYED-RELEASE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1999 RECENT MAJOR CHANGES Warnings and Precautions, Fundic Gland Polyps (5.10) 06/2018 INDICATIONS AND USAGE Rabeprazole sodium delayed-release tablets are a proton pump inhibitor (PPI) indicated in adults for: • • • • • • In adolescent patients 12 years of age and older for: • DOSAGE AND ADMINISTRATION INDIC ATIO N RECOMMENDED DOSAGE (2) Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) 20 mg once daily for 4 to 8 weeks Maintenance of Healing of Erosive or Ulcerative GERD studied for 12 months 20 mg once daily Symptomatic GERD in Adults 20 mg once daily for 4 weeks Healing of Duodenal Ulcers 20 mg once daily after morning meal for up to 4 weeks _Helicobacter pylori_ Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Three Drug Regimen: Rabeprazole sodium delayed-release tablets 20 mg Amoxicillin 1000 mg Clarithromycin 500 mg _All three medications should be taken twice daily with_ _morning and evening meals for 7 days_ Pathological Hypersecretory Conditions, Including Zollinger- Ellison Syndrome Starting dose 60 mg once daily then adjust to patient ne e ds Symptomatic GERD in Adolescents 12 Years of Age and Older 20 mg once daily for up to 8 weeks Administration Instructions (2): • • • • DOSAGE FORMS AND STRENGTHS Delayed-Release Tablets: 20 mg (3) CONTRAINDICATIONS Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) (1.1). Maintenance of Healing of Erosive or Ulcerative GERD (1.2). Treatment of Symptomatic GERD (1.3). Healing of Duodenal Ulcers (1.4). _Helicobacter pylori_ Eradication to Reduce the Risk of Duodenal Ulcer Izlasiet visu dokumentu